Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 10:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 2,665 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control II Clear all
Terminated Phase 2 Interventional Results available

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder

NCT00880399
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
orvepitant, placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
17
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Arcadia, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Oct 22, 2026, 10:45 AM EDT
Active, not recruiting Phase 2 Interventional

A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer

NCT04486378
View directory record Official record
Conditions
Colorectal Cancer Stage II, Colorectal Cancer Stage III
Interventions
RO7198457 intravenous (IV), Observational group (no intervention)
Drug · Other
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
15
States / cities
Greenbrae, California • Indianapolis, Indiana • Minneapolis, Minnesota + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 22, 2026, 10:45 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

SPARC - Screening for Lung Cancer With Platelets Via an AI-enabled RNA-based Classifier

NCT07460440
View directory record Official record
Conditions
Lung Cancer, Lung Nodule
Interventions
Platelet RNA-based assay
Diagnostic Test
Lead sponsor
University of Utah
Other
Eligibility
21 Years and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 22, 2026, 10:45 AM EDT
Active, not recruiting Not applicable Interventional

Improving Decision-Making Encounters in Lung Cancer Using a Low-Literacy Conversation Tool

NCT05407168
View directory record Official record
Conditions
Lung Carcinoma
Interventions
Best Practice, Health Promotion and Education, Questionnaire Administration
Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 99 Years
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Hillsboro, Oregon • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 22, 2026, 10:45 AM EDT
Recruiting Phase 1Phase 2 Interventional

Acceptance and Commitment Therapy for Adolescents and Young Adults With Sickle Cell Disease

NCT05685368
View directory record Official record
Conditions
Race-related Stress, Depression, Anxiety, Quality of Life, Stress Reaction
Interventions
ACT for SCD
Behavioral
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
14 Years to 21 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 22, 2026, 10:45 AM EDT
Completed Not applicable Interventional Results available

Insulin Dosage Software Program for People With Type 1 and Type 2 Diabetes

NCT01170208
View directory record Official record
Conditions
Diabetes, Insulin
Interventions
insulin dose software
Device
Lead sponsor
HealthPartners Institute
Other
Eligibility
21 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 22, 2026, 10:45 AM EDT
Not listed Phase 2 Interventional

A Randomized Trial of LOVAZA in Pediatric Sickle Cell Disease (SCD)

NCT01202812
View directory record Official record
Conditions
Sickle Cell Disease, HEMOGLOBIN SS, Hemoglobin S Beta-0 Thalassemia, Inflammation, Quality of Life
Interventions
Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA), Placebo Capsules
Dietary Supplement · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
10 Years to 19 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 25, 2010 · Synced Oct 22, 2026, 10:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Expressive Writing in Improving the Wellbeing or Comforting Capacity of Caregivers of Patients With Cancer

NCT02339870
View directory record Official record
Conditions
Caregiver
Interventions
Psychosocial Support for Caregiver, Questionnaire Administration, Sham Intervention
Other
Lead sponsor
University of Washington
Other
Eligibility
19 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 15, 2016 · Synced Oct 22, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis

NCT01532869
View directory record Official record
Conditions
Sclerosis, Systemic
Interventions
Placebo, tocilizumab [RoActemra/Actemra]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
21
States / cities
Los Angeles, California • San Diego, California • Stanford, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 22, 2026, 10:45 AM EDT
Completed Phase 2 Interventional

A Study of RX-10045 in the Treatment of Dry Eye Disease

NCT01675570
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
RX-10045, Vehicle for RX-10045
Drug
Lead sponsor
C.T. Development America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 8, 2013 · Synced Oct 22, 2026, 10:45 AM EDT
Completed Phase 2 Interventional Results available

Oral Nitrite in Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction

NCT03015402
View directory record Official record
Conditions
Pulmonary Hypertension Secondary, Heart Failure
Interventions
Sodium Nitrite, Placebo Oral Capsule
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 7, 2024 · Synced Oct 22, 2026, 10:45 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Down Syndrome Memantine Follow-up Study

NCT02304302
View directory record Official record
Conditions
Down Syndrome, Intellectual Disability
Interventions
Memantine, Placebo
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
15 Years to 32 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 22, 2026, 10:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Thyroid Dysfunction in Women With Newly Diagnosed Breast Cancer Compared to Healthy Volunteers

NCT00336102
View directory record Official record
Conditions
Breast Cancer, Fatigue, Hypothyroidism
Interventions
physiologic testing, fatigue assessment and management, management of therapy complications
Other · Procedure
Lead sponsor
University of South Florida
Other
Eligibility
20 Years to 80 Years · Female only
Enrollment
541 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2015
U.S. locations
41
States / cities
Phoenix, Arizona • Greeley, Colorado • Loveland, Colorado + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2015 · Synced Oct 22, 2026, 10:45 AM EDT
Completed Phase 2 Interventional

Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage

NCT01563445
View directory record Official record
Conditions
Acquired Bleeding Disorder, Intracerebral Haemorrhage
Interventions
activated recombinant human factor VII, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2017 · Synced Oct 22, 2026, 10:45 AM EDT
Terminated Phase 2 Interventional Results available

Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC

NCT03051672
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Pembrolizumab, Palliative radiotherapy
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 22, 2026, 10:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Individualized Assessment and Treatment for Alcoholism II

NCT03233802
View directory record Official record
Conditions
Alcoholism
Interventions
Individualized Assess & Treatment (IATP), Packaged Cognitive-Behavioral (PCBT), Case Management (CaseM)
Behavioral
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Oct 22, 2026, 10:45 AM EDT
Withdrawn Not applicable Interventional

StrataXRT for the Prevention and Treatment of Radiation Dermatitis in Breast Cancer or Head and Neck Cancer Patients

NCT05073172
View directory record Official record
Conditions
Breast Carcinoma, Head and Neck Carcinoma, Radiation-Induced Dermatitis
Interventions
Calendula Ointment, Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment, Polyethylene Glycol Hydrogel, Silicone-based Film Forming Topical Gel, Silver Sulfadiazine, Topical Hydrocortisone
Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Oct 22, 2026, 10:45 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness

NCT02965573
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
ARGX-113, Placebo
Biological · Drug
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
6
States / cities
Irvine, California • Los Angeles, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Oct 22, 2026, 10:45 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Executive Function Training for Children and Adolescents

NCT07147894
View directory record Official record
Conditions
Cognitive Change
Interventions
Nongamified N-back training, Gamified N-back training, Multiple Domain Training, Coaching Session
Behavioral
Lead sponsor
Northeastern University
Other
Eligibility
12 Years to 17 Years
Enrollment
780 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 22, 2026, 10:45 AM EDT
Completed Not applicable Interventional Results available

Impact of Pharmacy Clinic on Diabetes Management

NCT03377127
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Pharmacy Managed Diabetes Clinic (PMDC), Standard of Care (SOC)
Behavioral · Other
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years to 75 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Berkley, Michigan • Royal Oak, Michigan • Southfield, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 22, 2026, 10:45 AM EDT
Terminated Phase 3 Interventional Results available

Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)

NCT01077154
View directory record Official record
Conditions
Breast Cancer
Interventions
Placebo, Denosumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Female only
Enrollment
4,509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
93
States / cities
Birmingham, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 81 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 22, 2026, 10:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Virtual Reality Experiences for Anxiety and Pain Control

NCT04759183
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Survey Administration, Virtual Reality Game, Virtual Reality Meditation
Other · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 89 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 7, 2022 · Synced Oct 22, 2026, 10:45 AM EDT
Recruiting Not applicable Interventional

Acupressure for the Reduction of Anxiety in Patients Receiving Cancer-Directed Therapy

NCT06723041
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Acupressure Therapy, Acupressure Therapy - placebo, Acupressure Therapy - self-administered, Health Promotion and Education, Survey Administration
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 22, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Using EEG Operant Conditioning to Improve Trait Self-Control and Promote Healthy Behavior

NCT01801254
View directory record Official record
Conditions
Obesity, Type II Diabetes, Cardiovascular Disease, Health Behavior
Interventions
STRIDES, Sham Control
Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 22, 2026, 10:45 AM EDT